BELLUS Health Inc. (BLU) is up 2.30% in the pre-market trading session at the price of $4.89 after the announcement of positive findings from an interim analysis of the Phase 2b SOOTHE trial of BLU-5937. BLU is a clinical-stage biopharmaceutical company. It produces novel therapeutics to treat RCC and hypersensitization-related disorders.
Positive Results from Phase 2b SOOTHE Trail
On 13th September 2021, BLU published that interim analysis of its Phase 2b SOOTHE trial of BLU-5937 showed positive results. BLU-5937 is the highly selective P2X3 antagonist of the company to treat patients with refractory chronic cough (RCC). The refractory chronic cough (RCC) lasts more than eight weeks regardless of proper treatment for specific conditions. An estimated 9 million patients in the United States suffer from RCC. It adversely affects the physical, social, and psychosocial health of humans. Currently, there is no specific approved therapy for RCC, and treatment options are also limited.
CEO of BLU, Roberto Bellini, remarked that the encouraging SOOTHE Phase 2b trial interim analysis empowers them to accelerate their Phase 3 program while awaiting SOOTHE final results. With the development of their planned trial enrollment, they expect to announce topline data in the fourth quarter of 2021, he added.
BLU Second Quarter 2021 Earnings Report
On 11th August 2021, BLU announced its financial and operating results for the second quarter ending 30th June 2021. Roberto Bellini stated that their focus is to complete Phase 2 clinical trials of SOOTHE and BLUEPRINT. Both clinical trials are progressing and their topline results are expected in the fourth quarter of 2021. The upcoming milestones will help them to advance the development of BLU-5937, he added.
BLU reported net revenue of US$ 4,000 for the second quarter ended 30th June 2021. For the same quarter of the previous year, net revenues were US$ 6,000. For the quarter ended 30th June 2021, the net loss was US$17.8 million (US$0.23 per share). The net loss of US$8.4 million (US$0.14 per share), reported for the same period in 2020. Cash, cash equivalents, and short-term investments were US$72.3 million as of 30th June 2021. The net decrease has primarily resulted from the funds used to finance the operating activities related to product candidate BLU-5937. Net finance income was US$0.2 million for the quarter ended 30th June 2021, compared to US$0.9 million for the same quarter the previous year.